Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Insight Molecular Diagnostics Inc. Common Stock

IMDX

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

Last trade $1.78
Day change -$0.08 (-4.30%)
Day range $1.49 – $1.81
Volume 972,138
Market cap $61M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$60.87M
Price / earnings
—
Price / book
-2.86×
Price / sales
36.45×
EV / sales
25.82×
EV / EBITDA
-1.1×

Profitability

Earnings per share
-$1.51
Return on assets
-167.64%
Return on equity
231.74%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
2×
Quick ratio
1.98×
Cash ratio
1.73×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$30.88M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IMDX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025
Revenue$239K$32K$1.14M$260K$518K
Cost of revenue$82K$17K$643K$121K$180K
Gross profit$157K$15K$496K$139K$338K
Selling, general and administrative$4.79M$5.39M$4.62M$3.93M$4.11M
Research and development$4.49M$4.95M$5.83M$3.88M$3.27M
Total operating expenses$11.56M$10.35M$23.93M$11.19M$10.18M
Operating income-$11.4M-$10.33M-$23.44M-$11.05M-$9.84M
Interest expense-$20K$0-$26K-$29K-$25K
Income before taxes-$11.26M-$4.29M-$22.96M-$10.85M-$9.74M
Income taxes$0$0$0$0$0
Net income-$11.26M-$4.29M-$22.96M-$10.85M-$9.74M
Net income attributable to common shareholders-$11.26M-$4.29M-$22.96M-$10.85M-$9.74M
EBITDA-$10.74M-$9.7M-$8.27M-$10.46M-$9.28M
Basic earnings per share-$0.31-$0.12-$0.71-$0.34-$0.30
Diluted earnings per share-$0.31-$0.12-$0.71-$0.34-$0.30

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Medicare issued a favorable local coverage determination (LCD) for donor-derived cell-free DNA (dd-cfDNA) testing, expanding reimbursement for transplant organ monitoring. The policy increases surveillance testing frequencies across kidney and heart transplants compared to previous guidelines, supporting iMDx's commercial strategy for in-house testing kits. The company's flagship GraftAssureCore test is reimbursed at $2,753 per result, while GraftAssureDx awaits FDA marketing authorization.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.